Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of LN-144 in People With Metastatic Melanoma to the Brain

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Biological: Lifileucel (LN-144)

First Posted Date: 2022-12-07

Last Posted Date: 2024-10-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT05640193

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study of Tooth Erosion in People With Esophagogastric Cancer

Not Applicable

Recruiting

Conditions: Esophagogastric Cancer

Interventions: Other: Survey
Other: Intra-oral camera
Other: Optional Salvia sample

First Posted Date: 2022-11-10

Last Posted Date: 2024-04-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 300

Registration Number: NCT05612048

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Phase 2

Recruiting

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: ZEN003694

First Posted Date: 2022-11-07

Last Posted Date: 2024-01-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT05607108

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of LN-144 or LN-145 in People with Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Phase 1

Recruiting

Conditions: Uveal Melanoma
Melanoma
Metastatic Melanoma
Metastatic Uveal Melanoma

Interventions: Biological: Lifileucel (LN-144/LN-145)

First Posted Date: 2022-11-07

Last Posted Date: 2024-12-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT05607095

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, West Harrison, New York, United States

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Recruiting

Conditions: Breast Cancer

Interventions: Other: Physical Evaluation
Diagnostic Test: Dual-energy X-ray absorptiometry scans
Diagnostic Test: Trabecular Bone Score

First Posted Date: 2022-10-21

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 100

Registration Number: NCT05590949

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack, New York, United States

and more 4 locations

A Study of the EMPOWER Program for Latinx Caregivers of ICU Patients

Not Applicable

Withdrawn

Conditions: Informal Caregiver

Interventions: Behavioral: EMPOWER-Latinx

First Posted Date: 2022-10-21

Last Posted Date: 2023-11-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT05589883

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Phase 2

Recruiting

Conditions: Cutaneous Squamous Cell Carcinoma
Skin Cancer
Squamous Cell Carcinoma
Locally Advanced Squamous Cell Carcinoma
Locally Advanced Squamous Cell Carcinoma of the Skin
Locally Advanced Cutaneous Squamous Cell Carcinoma
Locally Advanced Skin Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Radiation: Radiotherapy

First Posted Date: 2022-10-10

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT05574101

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Cleveland Clinic (Data Collection Only), Cleveland, Ohio, United States
🇺🇸
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack, New York, United States

and more 10 locations

A Study of Brief Behavioral Activation for the Treatment of Depression in Older Adult Cancer Survivors

Phase 2

Recruiting

Conditions: Survivorship

Interventions: Behavioral: Behavioral Activation
Behavioral: Supportive Psychotherapy

First Posted Date: 2022-10-10

Last Posted Date: 2024-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 90

Registration Number: NCT05574127

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma
Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin's Lymphoma Refractory

Interventions: Radiation: Bridging radiotherapy (BRT)
Drug: Conditioning chemotherapy
Biological: CAR T-cell product

First Posted Date: 2022-10-10

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT05574114

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Triple-Negative Breast Cancer
Breast Cancer

Interventions: Drug: Eribulin
Drug: SDX-7320
Other: Placebo

First Posted Date: 2022-10-06

Last Posted Date: 2024-11-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 55

Registration Number: NCT05570253

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy